Clinical trials: Dual Antiplatelet Therapy
Ischemic Stroke, TIA
Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events
Nondisabling cerebrovascular events represent the largest group of cerebrovascular disease with a high risk of recurrent stroke.
- Trial name
- ADANCE (NCT01924325)
- Testing
- Apixaban, Clopidogrel, Aspirin
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Xijing Hospital
Acute Myocardial Infarction, Coronary Syndrome
Antiplatelet Therapy Following Stent Implantation
Coronary artery stents, particularly drug-eluting stents (DES), are used in the majority of patients who undergo percutaneous coronary intervention (PCI) to improve symptoms in patients with obstructive coronary artery disease.
- Conditions
- Acute Myocardial Infarction, Coronary Syndrome, Angina, Unstable
- Trial name
- Anti-Clot (NCT02051361)
- Where
- Greece
- Volunteers
- 900 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Platelet Aggregation, Adenosine
Platelet Aggregation in Patients With Coronary Artery Disease and Kidney Dysfunction Taking Clopidogrel or Ticagrelor
About 35% of patients hospitalized with Acute Coronary Syndromes (ACS) have some degree of renal dysfunction. Chronic kidney disease (CKD) is not only associated to worse prognosis in ACS patients, but leads also to an increased…
- Conditions
- Platelet Aggregation, Adenosine, Coronary Artery Disease, Kidney Dysfunction
- Trial name
- NCT03039205
- Testing
- Clopidogrel, Ticagrelor
- Where
- Brazil
- Volunteers
- 90 people
- Sponsor
- University of Sao Paulo
Coronary Artery Disease
A New Strategy Regarding Discontinuation of Dual Antiplatelet
Drug-eluting stents (DES), markedly reducing the neointimal hyperplasia after stent implantation compared with bare-metal stents (BMS), have improved angiographic and clinical outcomes in the complex lesions and patients with…
- Trial name
- NCT01145079
- Testing
- Zotarolimus-eluting stent, Zotarolimus-eluting stent for ACS and DM, Everolimus-eluting stent for long lesion
- Where
- South Korea
- Volunteers
- 982 people
- Sponsor
- Yonsei University
Elevated Lipoprotein(a) Level, Coronary Artery Disease
24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized Trial
1. Main objective Among patients with elevated Lp(a) levels (>30mg/dL) who did not experience cardiovascular events or BARC type 2, 3, or 5 bleeding within 12 months after PCI and DES implantation, was it possible to reduce the…
- Conditions
- Elevated Lipoprotein(a) Level, Coronary Artery Disease, Drug-Eluting Stent, Dual Antiplatelet Therapy
- Trial name
- DAPT-Lp(a) (NCT06014060)
- Testing
- 24 Months DAPT, 12 Months DAPT
- Where
- China
- Volunteers
- 3,300 people
- Sponsor
- China National Center for Cardiovascular Diseases
Coronary Artery Disease
EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events
EDUCATE is a prospective, multi-center study designed to collect real-world safety and clinical outcomes in subjects receiving one or more Endeavor Zotarolimus-Eluting Stents and either clopidogrel and aspirin or prasugrel and…
- Trial name
- EDUCATE (NCT01069003)
- Testing
- Thienopyridine Therapy, Surveillance Arm
- Where
- United States
- Volunteers
- 2,272 people
- Sponsor
- Medtronic Vascular
Intracranial Arteriosclerosis, Intracranial Artery Stenosis
Comparison Three vs Six Months of Dual Anti-platelet Therapy After Sirolimus-eluting Stent Implantation
This study is a prospective, multicenter, open-label, randomized controlled clinical trial, aims to assess the clinical non-inferiority of 3 months (short-term) vs 6 months (long-term) of Dual Anti-Platelet Therapy (DAPT) in…
- Conditions
- Intracranial Arteriosclerosis, Intracranial Artery Stenosis, Drug-Eluting Stents
- Trial name
- NCT06857045
- Testing
- NOVA intracranial sirolimus-eluting stent system
- Where
- China
- Sponsor
- Sino Medical Sciences Technology Inc.
High Ischemic Risk
24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial
The purpose of this prospective randomized clinical trial is to compare the clinical outcomes between aspirin with ticagrelor versus aspirin with clopidogrel in high ischemic risk patients beyond 12 months after percutaneous…
- Trial name
- NCT04989257
- Testing
- Ticagrelor-based dual-antiplatelet therapy, Clopidogrel-based dual-antiplatelet therapy
- Where
- South Korea
- Volunteers
- 3,488 people
- Sponsor
- Yonsei University
Cardiovascular Disease, Coronary Artery Disease
Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention
Balloon angioplasty (Percutaneous Coronary Intervention (PCI)) is commonly used to treat patients with obstructive coronary artery disease (CAD).
- Trial name
- X-PLORER (NCT01442792)
- Testing
- UFH, Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban (Xarelto, BAY59-7939) and UFH
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 108 people
- Sponsor
- Bayer
Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)
Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)
The primary aim of this study is to investigate the PD effects of switching from standard-dose clopidogrel dose to low-dose prasugrel versus continuing standard-dose clopidogrel in patients at dual-risk (HBR defined as the…
- Trial name
- NCT07025148
- Testing
- Prasugrel, Clopidogrel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Florida
Gastric Ulcer Induced by Antiplatelet Agent, Ulcer of the Gastrointestinal Tract
Proton Pump Inhibitor Prevent Dual Antiplatelet Agents Induced Gastrointestinal Ulcer After Coronary Artery Bypass Graft
The purpose of this study is to determine whether 12-month prophylactic treatment with pantoprazole is superior to 1-month therapy without major cardiovascular events (MACE) increased significantly, in prevention of dual…
- Conditions
- Gastric Ulcer Induced by Antiplatelet Agent, Ulcer of the Gastrointestinal Tract, Proton Pump Inhibitor
- Trial name
- DACAB-GI-2 (NCT03038009)
- Testing
- Pantoprazole
- Where
- China
- Sponsor
- Ruijin Hospital
Thrombosis, Bleeding
Multi-Omics-Based Novel Thrombosis and Bleeding Markers and Risk Model for CHD
Patients with coronary heart disease who take dual antiplatelet therapy face two serious risks: thrombosis and major bleeding. This study aims to develop better ways to predict these risks and guide personalized treatment.
- Conditions
- Thrombosis, Bleeding, Coronary Artery Disease (CAD)
- Trial name
- NCT07523880
- Where
- 3 sites in China
- Volunteers
- 12,154 people
- Sponsor
- Xueyan Zhao
Intracranial Aneurysm, Aneurysm
Coated Mongolian Aneurysm Treatment Study 1
The purpose of this study is to assess safety and effectiveness of the p64 MW HPC or p48 MW HPC Flow Modulation Device under Dual Antiplatelet Medication.
- Conditions
- Intracranial Aneurysm, Aneurysm, Vascular Diseases
- Trial name
- COMATS 1 (NCT04305626)
- Testing
- Endovascular treatment of intracranial aneurysms
- Where
- Mongolia
- Volunteers
- 90 people
- Sponsor
- Phenox GmbH
Coronary Heart Disease (CHD)
Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)
This investigator-initiated, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) utilizing a P2Y12 inhibitor compared to dual antiplatelet therapy (DAPT) in…
- Trial name
- KONG-FREEDOM-I (NCT07587099)
- Testing
- Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT)
- Where
- 14 sites in China
- Volunteers
- 2,170 people
- Sponsor
- Gan Lijun
Coronary Artery Disease, Percutaneous Coronary Intervention
Patient Centered Machine Learning Model for Bleeding and Ischemic Risk
Dual antiplatelet therapy (DAPT) is indicated in all patients undergoing coronary stent implantation to prevent ischemic recurrencies despite an increased risk of bleeding.
- Trial name
- xDAPT (NCT06089304)
- Testing
- Percutaneous coronary intervention
- Where
- United States
- Volunteers
- 19,000 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors
Ticagrelor currently represents the most tested and commonly used P2Y12 inhibitor monotherapy following percutaneous coronary intervention.
- Trial name
- SWAP-7 (NCT06691191)
- Testing
- Ticagrelor 90 mg, Prasugrel 10 mg
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Florida
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), Dual Anti-platelet Therapy
Aspirin-Free Strategy After 3-6 Month Dual Antiplatelet Therapy in Acute Coronary Syndrome
This randomized controlled trial aims to evaluate the safety and efficacy of an aspirin-free strategy after 3-6 months of dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) who have undergone complete…
- Trial name
- NCT07736196
- Testing
- Aspirin-Free Strategy, Dual Antiplatelet Therapy
- Where
- Egypt
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Assiut University
Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement
Dual AntiPlatelet Therapies for Prevention of Periinterventional Embolic Events in TAVI
TAVI is increasingly adopted as standard treatment for many subgroups of patients with aortic stenosis. However, due to a lack of data there is yet no TAVI-specific guidance regarding the optimum periinterventional drug regimen.
- Conditions
- Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement, Intracranial Embolism
- Trial name
- DAPT-TAVI (NCT03001960)
- Testing
- Preloading before TAVI, Postloading after TAVI
- Volunteers
- 200 people
- Sponsor
- Charite University, Berlin, Germany
Abdominal Aortic Aneurysms (AAA), Endovascular Aneurysm Repair (EVAR)
Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair
This study was a target trial emulation using the National Health Claims database established by the Korean National Health Insurance Service (K-NHIS). 8,325 patients were included.
- Trial name
- EVAR_DAPT_SAPT (NCT06876727)
- Volunteers
- 8,325 people
- Sponsor
- Samsung Medical Center
Coronary Artery Disease
The Study to Evaluate the Safety and Efficacy of the Onyx Family
Observation of the safety and efficacy of 1-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention using Onyx family stents in elderly patients aged 75 years or older
- Trial name
- NCT06577896
- Testing
- Onyx family
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Pusan National University Yangsan Hospital